Patented technology for the production of full-length, correctly folded and functional proteins
Identify all autoantigens and antigens that make up the Autoproteome*
(*) Totality of all possible autoantigens and neoantigens representing a given disease and its sub-types
Quantify autoantibodies using a pin-prick of blood
Autoantigen discovery database
Bespoke content and project design services
Sengenics believes that forging strong external alliances is an essential part of our strategy to access great science. Sengenics is pursuing potential collaborators for early stage opportunities in order to identify and develop innovative products in the following areas of interest:
The KREX technology (KREX) or discoveries using KREX can be licensed. Sengenics also has a royalty model depending on specific scenarios as shown below:
KREX technology license (iTAP)
Full technology transfer of KREX. Sengenics grants a site-specific, restricted use, royalty bearing license to KREX-related patents. In addition, full training and on-site support is provided.
Biomarker IP license and Royalties
Sengenics has more than a dozen signed collaboration agreements for a variety of mass market addressable conditions such as Lung Cancer, Zika, Autism, Ageing, Transplantation Rejection and Prostate Cancer.
Royalties on companion diagnostics
Sengenics has a number of collaborations with top pharma and academic institutions in which patients from clinical drug trials have been stratified into responders and non-responders. The 2 main classes of drugs that have been addressed are cancer immunotherapy immune checkpoint inhibitors and drugs for autoimmune diseases.
We’d love to hear more about your work and perspective. Let’s start a conversation by filling up the form below: